Michael Gerard Morley, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cataract | 8 | 2019 | 832 | 0.700 |
Why?
|
| Macular Edema | 4 | 2023 | 374 | 0.680 |
Why?
|
| Insurance, Liability | 1 | 2019 | 101 | 0.650 |
Why?
|
| Liability, Legal | 1 | 2019 | 210 | 0.610 |
Why?
|
| Anesthesia, Local | 1 | 2019 | 277 | 0.580 |
Why?
|
| Eye Diseases | 2 | 2020 | 653 | 0.570 |
Why?
|
| Visual Acuity | 12 | 2022 | 2672 | 0.530 |
Why?
|
| Retinal Detachment | 5 | 2016 | 428 | 0.510 |
Why?
|
| Scleral Buckling | 1 | 2016 | 95 | 0.500 |
Why?
|
| Malpractice | 1 | 2019 | 556 | 0.480 |
Why?
|
| Retinal Vein Occlusion | 2 | 2006 | 149 | 0.470 |
Why?
|
| Vitrectomy | 3 | 2016 | 392 | 0.470 |
Why?
|
| Cataract Extraction | 4 | 2018 | 467 | 0.470 |
Why?
|
| Interprofessional Relations | 1 | 2019 | 990 | 0.440 |
Why?
|
| Retinal Necrosis Syndrome, Acute | 2 | 2010 | 24 | 0.380 |
Why?
|
| Cryosurgery | 1 | 2016 | 474 | 0.360 |
Why?
|
| Treatment Failure | 1 | 2016 | 2644 | 0.340 |
Why?
|
| Cytomegalovirus Retinitis | 4 | 1998 | 56 | 0.330 |
Why?
|
| Emergency Medical Technicians | 1 | 2010 | 119 | 0.330 |
Why?
|
| Eye Infections, Viral | 1 | 2010 | 60 | 0.330 |
Why?
|
| Diabetic Retinopathy | 3 | 2024 | 1274 | 0.330 |
Why?
|
| Ganciclovir | 5 | 1998 | 252 | 0.320 |
Why?
|
| Herpesviridae Infections | 1 | 2010 | 270 | 0.310 |
Why?
|
| Laser Therapy | 4 | 2010 | 1092 | 0.300 |
Why?
|
| Eye Injuries | 1 | 2010 | 227 | 0.280 |
Why?
|
| Eyeglasses | 1 | 2008 | 137 | 0.280 |
Why?
|
| Blast Injuries | 1 | 2010 | 322 | 0.270 |
Why?
|
| AIDS-Related Opportunistic Infections | 4 | 1998 | 662 | 0.260 |
Why?
|
| Laser Coagulation | 2 | 2020 | 330 | 0.250 |
Why?
|
| Vision Disorders | 2 | 2022 | 1088 | 0.240 |
Why?
|
| Antiviral Agents | 4 | 2010 | 3060 | 0.230 |
Why?
|
| Bhutan | 5 | 2023 | 61 | 0.220 |
Why?
|
| Geographic Atrophy | 1 | 2022 | 91 | 0.190 |
Why?
|
| Retinal Diseases | 2 | 2020 | 705 | 0.180 |
Why?
|
| Emergency Medicine | 1 | 2010 | 1198 | 0.180 |
Why?
|
| Wet Macular Degeneration | 1 | 2022 | 162 | 0.170 |
Why?
|
| Long QT Syndrome | 2 | 2014 | 467 | 0.170 |
Why?
|
| Vitreous Body | 2 | 2020 | 399 | 0.160 |
Why?
|
| Massachusetts | 6 | 2019 | 8830 | 0.150 |
Why?
|
| Myocardium | 4 | 2017 | 4725 | 0.140 |
Why?
|
| Quantitative Trait Loci | 2 | 2015 | 2116 | 0.140 |
Why?
|
| Pyruvic Acid | 1 | 2017 | 204 | 0.140 |
Why?
|
| Program Evaluation | 1 | 2005 | 2495 | 0.130 |
Why?
|
| Polymorphism, Single Nucleotide | 7 | 2017 | 15936 | 0.130 |
Why?
|
| Myocytes, Cardiac | 2 | 2015 | 1668 | 0.130 |
Why?
|
| Expert Testimony | 1 | 2018 | 364 | 0.130 |
Why?
|
| Receptors, Cytokine | 1 | 2016 | 258 | 0.120 |
Why?
|
| Reoperation | 5 | 2016 | 4303 | 0.120 |
Why?
|
| Insurance Claim Review | 1 | 2019 | 741 | 0.120 |
Why?
|
| Health Personnel | 2 | 2019 | 3335 | 0.120 |
Why?
|
| Blindness | 2 | 2022 | 584 | 0.120 |
Why?
|
| Pulmonary Alveoli | 1 | 2017 | 652 | 0.120 |
Why?
|
| Fundus Oculi | 3 | 2024 | 556 | 0.120 |
Why?
|
| Gene Expression Profiling | 4 | 2018 | 9420 | 0.110 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2017 | 543 | 0.110 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 1 | 2016 | 251 | 0.110 |
Why?
|
| Adipose Tissue, White | 1 | 2016 | 365 | 0.110 |
Why?
|
| Epithelium | 1 | 2018 | 1603 | 0.110 |
Why?
|
| Photography | 1 | 2016 | 532 | 0.110 |
Why?
|
| Retrospective Studies | 14 | 2023 | 80646 | 0.100 |
Why?
|
| Visually Impaired Persons | 1 | 2013 | 78 | 0.100 |
Why?
|
| Mass Screening | 2 | 2005 | 5428 | 0.090 |
Why?
|
| Humans | 46 | 2024 | 761572 | 0.090 |
Why?
|
| Sequence Analysis, RNA | 3 | 2018 | 2020 | 0.090 |
Why?
|
| Male | 28 | 2024 | 360842 | 0.090 |
Why?
|
| Aged | 19 | 2020 | 169310 | 0.090 |
Why?
|
| Adipose Tissue, Brown | 1 | 2016 | 764 | 0.090 |
Why?
|
| Pluripotent Stem Cells | 1 | 2017 | 799 | 0.090 |
Why?
|
| Lenses, Intraocular | 1 | 1992 | 139 | 0.090 |
Why?
|
| Female | 30 | 2024 | 392686 | 0.090 |
Why?
|
| Retina | 2 | 2024 | 2659 | 0.090 |
Why?
|
| Learning | 1 | 2019 | 1740 | 0.090 |
Why?
|
| Mendelian Randomization Analysis | 1 | 2016 | 1007 | 0.090 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2016 | 1136 | 0.090 |
Why?
|
| Eyelid Neoplasms | 1 | 1991 | 89 | 0.090 |
Why?
|
| Fluorescein Angiography | 3 | 2022 | 1059 | 0.090 |
Why?
|
| Calcium Signaling | 1 | 2014 | 733 | 0.080 |
Why?
|
| Explosions | 1 | 2010 | 108 | 0.080 |
Why?
|
| Uric Acid | 1 | 2016 | 807 | 0.080 |
Why?
|
| Middle Aged | 18 | 2024 | 220920 | 0.080 |
Why?
|
| Orbital Neoplasms | 1 | 1991 | 222 | 0.080 |
Why?
|
| Qualitative Research | 1 | 2019 | 3023 | 0.080 |
Why?
|
| Forkhead Transcription Factors | 1 | 2016 | 1616 | 0.080 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2014 | 829 | 0.080 |
Why?
|
| Lung | 2 | 2018 | 10002 | 0.080 |
Why?
|
| Databases, Factual | 2 | 2024 | 7967 | 0.080 |
Why?
|
| Drug Delivery Systems | 2 | 1996 | 2226 | 0.070 |
Why?
|
| Genetic Loci | 1 | 2017 | 2632 | 0.070 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2016 | 2057 | 0.070 |
Why?
|
| Terrorism | 1 | 2010 | 211 | 0.070 |
Why?
|
| Postoperative Care | 2 | 2017 | 1468 | 0.070 |
Why?
|
| Drug Implants | 3 | 1998 | 230 | 0.070 |
Why?
|
| Referral and Consultation | 1 | 2020 | 3600 | 0.070 |
Why?
|
| Sex Distribution | 3 | 2013 | 2281 | 0.070 |
Why?
|
| Single-Cell Analysis | 1 | 2018 | 2450 | 0.070 |
Why?
|
| Genome-Wide Association Study | 5 | 2017 | 12690 | 0.070 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2016 | 2803 | 0.070 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2018 | 1860 | 0.070 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2022 | 2047 | 0.070 |
Why?
|
| Age Distribution | 3 | 2013 | 2880 | 0.070 |
Why?
|
| Carcinoma, Basal Cell | 1 | 1991 | 560 | 0.060 |
Why?
|
| Choroidal Neovascularization | 1 | 2009 | 363 | 0.060 |
Why?
|
| Heart Ventricles | 2 | 2014 | 3807 | 0.060 |
Why?
|
| Belize | 1 | 2005 | 15 | 0.060 |
Why?
|
| Models, Genetic | 1 | 2015 | 3442 | 0.060 |
Why?
|
| Epithelial Cells | 1 | 2017 | 3677 | 0.060 |
Why?
|
| Aged, 80 and over | 7 | 2020 | 58986 | 0.060 |
Why?
|
| Follow-Up Studies | 9 | 2009 | 39107 | 0.060 |
Why?
|
| Repressor Proteins | 1 | 2016 | 2986 | 0.060 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1994 | 2199 | 0.060 |
Why?
|
| Cisplatin | 1 | 1991 | 1652 | 0.060 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2016 | 3612 | 0.060 |
Why?
|
| Adult | 11 | 2024 | 221203 | 0.060 |
Why?
|
| Hypertension | 1 | 2005 | 8540 | 0.060 |
Why?
|
| Gene Expression | 2 | 2015 | 7581 | 0.060 |
Why?
|
| Diabetes Mellitus | 1 | 2023 | 5841 | 0.060 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2016 | 4513 | 0.060 |
Why?
|
| Myocardial Ischemia | 1 | 2014 | 2113 | 0.060 |
Why?
|
| Heart Diseases | 1 | 2017 | 2781 | 0.060 |
Why?
|
| Genes, Reporter | 2 | 2018 | 1529 | 0.060 |
Why?
|
| Child, Preschool | 3 | 2020 | 42230 | 0.060 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2014 | 2898 | 0.060 |
Why?
|
| Cell Differentiation | 2 | 2018 | 11530 | 0.050 |
Why?
|
| Health Status Indicators | 1 | 2008 | 970 | 0.050 |
Why?
|
| Macular Degeneration | 2 | 2009 | 1007 | 0.050 |
Why?
|
| DNA Methylation | 1 | 2016 | 4399 | 0.050 |
Why?
|
| Self Care | 1 | 2007 | 796 | 0.050 |
Why?
|
| Lentivirus | 2 | 2015 | 508 | 0.050 |
Why?
|
| Postoperative Complications | 4 | 2018 | 15633 | 0.050 |
Why?
|
| HEK293 Cells | 3 | 2016 | 4280 | 0.050 |
Why?
|
| Coronary Disease | 1 | 2016 | 5914 | 0.050 |
Why?
|
| Drug Therapy, Combination | 2 | 2010 | 6312 | 0.050 |
Why?
|
| Heart Failure | 2 | 2016 | 11670 | 0.050 |
Why?
|
| Depressive Disorder | 2 | 2007 | 3728 | 0.050 |
Why?
|
| Adolescent | 4 | 2022 | 88324 | 0.040 |
Why?
|
| Time Factors | 3 | 2018 | 39970 | 0.040 |
Why?
|
| Cell Separation | 2 | 2017 | 1720 | 0.040 |
Why?
|
| Child | 4 | 2020 | 80156 | 0.040 |
Why?
|
| Glucocorticoids | 1 | 2010 | 2161 | 0.040 |
Why?
|
| Cooperative Behavior | 1 | 2007 | 1505 | 0.040 |
Why?
|
| Ophthalmology | 1 | 1986 | 550 | 0.040 |
Why?
|
| Uganda | 1 | 2024 | 1332 | 0.040 |
Why?
|
| Vision Tests | 1 | 2020 | 161 | 0.040 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2016 | 9002 | 0.040 |
Why?
|
| Treatment Outcome | 7 | 2016 | 64684 | 0.040 |
Why?
|
| MicroRNAs | 1 | 2015 | 3816 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2011 | 3639 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2024 | 2079 | 0.040 |
Why?
|
| Aspirin | 1 | 2010 | 3133 | 0.040 |
Why?
|
| Prevalence | 3 | 2023 | 15732 | 0.040 |
Why?
|
| Herpes Zoster Ophthalmicus | 1 | 1998 | 37 | 0.040 |
Why?
|
| Vision, Low | 1 | 2020 | 163 | 0.040 |
Why?
|
| Patient Participation | 1 | 2007 | 1445 | 0.040 |
Why?
|
| B-Lymphocytes | 1 | 2011 | 4758 | 0.040 |
Why?
|
| Retinal Perforations | 1 | 1999 | 138 | 0.040 |
Why?
|
| Acyclovir | 2 | 1998 | 268 | 0.040 |
Why?
|
| Pulmonary Surfactants | 1 | 2017 | 162 | 0.030 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2016 | 103 | 0.030 |
Why?
|
| Cross-Sectional Studies | 3 | 2023 | 26127 | 0.030 |
Why?
|
| Citric Acid Cycle | 1 | 2017 | 231 | 0.030 |
Why?
|
| Spheroids, Cellular | 1 | 2018 | 330 | 0.030 |
Why?
|
| Solubility | 1 | 2018 | 1091 | 0.030 |
Why?
|
| Lasers | 1 | 2020 | 952 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2022 | 3492 | 0.030 |
Why?
|
| Proteins | 1 | 2011 | 6032 | 0.030 |
Why?
|
| Cell Respiration | 1 | 2016 | 201 | 0.030 |
Why?
|
| Genotype | 3 | 2016 | 12990 | 0.030 |
Why?
|
| Transcription Factors | 4 | 2016 | 12129 | 0.030 |
Why?
|
| Developing Countries | 1 | 2008 | 2885 | 0.030 |
Why?
|
| Pregnancy | 1 | 2017 | 29876 | 0.030 |
Why?
|
| Endoderm | 1 | 2016 | 160 | 0.030 |
Why?
|
| Anterior Eye Segment | 1 | 2016 | 143 | 0.030 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2016 | 1058 | 0.030 |
Why?
|
| Genes, Homeobox | 1 | 2016 | 285 | 0.030 |
Why?
|
| Mice | 6 | 2018 | 81533 | 0.030 |
Why?
|
| Organogenesis | 1 | 2016 | 215 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2016 | 386 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2005 | 2690 | 0.030 |
Why?
|
| Deoxyribonucleases | 1 | 2015 | 211 | 0.030 |
Why?
|
| Alleles | 2 | 2016 | 6864 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2016 | 23996 | 0.030 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2016 | 318 | 0.030 |
Why?
|
| Quality of Life | 2 | 2022 | 13367 | 0.030 |
Why?
|
| Cell Line | 2 | 2018 | 15601 | 0.030 |
Why?
|
| Stroke | 1 | 2016 | 9758 | 0.030 |
Why?
|
| Wnt Proteins | 1 | 2017 | 718 | 0.030 |
Why?
|
| Progesterone | 1 | 2017 | 742 | 0.030 |
Why?
|
| Young Adult | 1 | 2019 | 59255 | 0.030 |
Why?
|
| Conserved Sequence | 1 | 2016 | 1163 | 0.030 |
Why?
|
| Prognosis | 3 | 2016 | 29629 | 0.030 |
Why?
|
| Pigment Epithelium of Eye | 1 | 1993 | 209 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2009 | 9177 | 0.030 |
Why?
|
| Lactic Acid | 1 | 2017 | 1139 | 0.020 |
Why?
|
| Self Efficacy | 1 | 2016 | 638 | 0.020 |
Why?
|
| Cytoplasm | 1 | 2016 | 1510 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2016 | 2180 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2016 | 12148 | 0.020 |
Why?
|
| Sensitivity and Specificity | 2 | 2024 | 14666 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2016 | 1612 | 0.020 |
Why?
|
| Organ Specificity | 1 | 2016 | 1968 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2016 | 1814 | 0.020 |
Why?
|
| Electrocardiography | 2 | 2014 | 6377 | 0.020 |
Why?
|
| Severity of Illness Index | 2 | 2006 | 15843 | 0.020 |
Why?
|
| Cell Proliferation | 2 | 2017 | 10448 | 0.020 |
Why?
|
| Morbidity | 1 | 2016 | 1750 | 0.020 |
Why?
|
| Choroid | 1 | 1993 | 360 | 0.020 |
Why?
|
| Kinetics | 1 | 2018 | 6374 | 0.020 |
Why?
|
| Animals | 6 | 2018 | 168467 | 0.020 |
Why?
|
| Infant, Newborn | 2 | 2020 | 26198 | 0.020 |
Why?
|
| Epigenomics | 1 | 2015 | 943 | 0.020 |
Why?
|
| Necrosis | 1 | 1994 | 1611 | 0.020 |
Why?
|
| Fatty Acids | 1 | 2017 | 1808 | 0.020 |
Why?
|
| Recurrence | 3 | 1998 | 8466 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2005 | 8481 | 0.020 |
Why?
|
| Cell Lineage | 1 | 2018 | 2556 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2016 | 2665 | 0.020 |
Why?
|
| Exudates and Transudates | 1 | 2009 | 174 | 0.020 |
Why?
|
| Orbit | 1 | 1991 | 457 | 0.020 |
Why?
|
| Health Surveys | 2 | 2013 | 4061 | 0.020 |
Why?
|
| DNA, Complementary | 1 | 2011 | 1991 | 0.020 |
Why?
|
| Binding Sites | 1 | 2016 | 6056 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 2015 | 2330 | 0.020 |
Why?
|
| Lung Diseases | 1 | 2017 | 1909 | 0.020 |
Why?
|
| Gene Expression Regulation | 2 | 2016 | 11904 | 0.020 |
Why?
|
| Genetic Variation | 2 | 2016 | 6567 | 0.020 |
Why?
|
| Prosthesis Failure | 1 | 1992 | 1204 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2015 | 2932 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 1991 | 2218 | 0.020 |
Why?
|
| Base Sequence | 1 | 2017 | 12441 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2011 | 1699 | 0.020 |
Why?
|
| Injections | 1 | 2009 | 831 | 0.020 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2014 | 1555 | 0.020 |
Why?
|
| Regeneration | 1 | 2015 | 1512 | 0.020 |
Why?
|
| Medication Adherence | 1 | 2017 | 2176 | 0.020 |
Why?
|
| Internship and Residency | 1 | 1986 | 5882 | 0.020 |
Why?
|
| Glucose | 1 | 2017 | 4346 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2016 | 8321 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2020 | 6391 | 0.020 |
Why?
|
| Intraoperative Complications | 1 | 1992 | 1166 | 0.020 |
Why?
|
| Urban Population | 1 | 2013 | 2036 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2015 | 5869 | 0.010 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2014 | 2244 | 0.010 |
Why?
|
| Lipids | 1 | 2015 | 3341 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2016 | 9646 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2016 | 17904 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2014 | 5790 | 0.010 |
Why?
|
| Mitochondria | 1 | 2016 | 3624 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 1991 | 3597 | 0.010 |
Why?
|
| Phenotype | 2 | 2014 | 16592 | 0.010 |
Why?
|
| Rural Population | 1 | 2013 | 2285 | 0.010 |
Why?
|
| Zebrafish | 1 | 2014 | 3007 | 0.010 |
Why?
|
| Signal Transduction | 2 | 2016 | 23447 | 0.010 |
Why?
|
| Japan | 1 | 2007 | 1378 | 0.010 |
Why?
|
| DNA | 1 | 2016 | 7213 | 0.010 |
Why?
|
| Neovascularization, Pathologic | 1 | 1993 | 2644 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2016 | 5799 | 0.010 |
Why?
|
| Genetics, Population | 1 | 2007 | 937 | 0.010 |
Why?
|
| Heart | 1 | 2015 | 4404 | 0.010 |
Why?
|
| Models, Biological | 1 | 2017 | 9469 | 0.010 |
Why?
|
| Clinical Competence | 1 | 2016 | 4793 | 0.010 |
Why?
|
| Gene Frequency | 1 | 2007 | 3606 | 0.010 |
Why?
|
| Caribbean Region | 1 | 1999 | 191 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2015 | 18965 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2017 | 22172 | 0.010 |
Why?
|
| Foscarnet | 1 | 1998 | 35 | 0.010 |
Why?
|
| Sampling Studies | 1 | 1999 | 615 | 0.010 |
Why?
|
| Infant | 1 | 2020 | 36192 | 0.010 |
Why?
|
| Patient Education as Topic | 1 | 2007 | 2319 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2007 | 5247 | 0.010 |
Why?
|
| Tomography, Optical Coherence | 1 | 2009 | 2917 | 0.010 |
Why?
|
| Health Services Accessibility | 1 | 2013 | 5440 | 0.010 |
Why?
|
| Delayed-Action Preparations | 1 | 1998 | 962 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 1999 | 2927 | 0.010 |
Why?
|
| Myocardial Infarction | 1 | 2015 | 11461 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2017 | 54426 | 0.010 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2007 | 3205 | 0.010 |
Why?
|
| Risk Factors | 2 | 2016 | 74213 | 0.010 |
Why?
|
| ROC Curve | 1 | 1999 | 3579 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2014 | 41493 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1991 | 20571 | 0.000 |
Why?
|
| Pilot Projects | 1 | 1999 | 8633 | 0.000 |
Why?
|
| Incidence | 1 | 1999 | 21355 | 0.000 |
Why?
|
| Disease Progression | 1 | 1998 | 13510 | 0.000 |
Why?
|
| United States | 1 | 1986 | 72335 | 0.000 |
Why?
|